James M. Hollands, PharmD, BCPS, (AQ Cardiology)

James M. Hollands, PharmD, BCPS, (AQ Cardiology)

James M. Hollands PharmD

Associate Professor of Clinical Pharmacy

Education

PharmD, Wilkes University

Pharmacy Practice Residency, Barnes Jewish Hospital

Critical Care Specialty Residency, Barnes Jewish Hospital

Research Interests

  • Cardiology
  • Critical Care
  • Medication dosing in obesity
  • Infectious diseases

Synopsis

Dr. James M. Hollands is an Associate Professor of Clinical Pharmacy in the Department of Pharmacy Practice and Pharmacy Administration at the Philadelphia College of Pharmacy, University of the Sciences. His clinical practice site is in intensive care units at Cooper University Hospital in Camden, NJ.

Dr. Hollands earned his Doctor of Pharmacy degree with a minor in psychology from Wilkes University in Wilkes-Barre, Pennsylvania. He pursued his post-graduate training at Barnes Jewish Hospital in St. Louis, Missouri, where he completed both his pharmacy practice and critical care specialty residencies.

For over eight years, Dr. Hollands was the clinical pharmacist for the Cardiac Intensive Care Unit and Cardiac Procedure Center at Barnes Jewish Hospital. During that time, he was actively involved with research, scholarship, and hospital committee service as well as education of residents and students. In 2008, he was appointed the residency program director for the PGY2 critical care residency at Barnes Jewish Hospital.

Dr. Hollands is an active member of American College of Clinical Pharmacy, American Society of Health-System Pharmacists, American College of Cardiology, American Heart Association, and Society of Critical Care Medicine, as well as numerous regional organizations. He is on the editorial board for Annals of Pharmacotherapy and an expert guest surveyor for PGY2 critical care residency accreditation surveys for ASHP. His research interests include anticoagulation, antiplatelet therapy, medication dosing in obesity, acute coronary syndromes, advanced cardiac life support, shock, and hemodynamics. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology.

Selected Scholarly Activity

Hagopian JC, Riney JN, Hollands JM, Deal EN.  Assessment of bleeding risk associated with therapeutic enoxaparin in the morbidly obese. Ann Pharmacother. (In press).

Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffmann J, Micek ST, Kollef MH. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother. 2013;47:170-80.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM. Role of new drugs for management of atrial fibrillation. Ann Pharmacother. 2012;46:1656-70.

Barnes BJ, Hollands JM, Cuculich PS. Chapter 5: Drug-induced conduction-related complications. In: Papadopoulos J, Cooper B, Kane-Gill S, Mallow Corbett S, Barletta J, eds. Drug-Induced Complications in the Critically Ill Patient: A Guide for Recognition and Treatment. 1st ed. Mount Prospect, IL: Society of Critical Care Medicine, 2012: 63-74.

Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series: J Thromb Thrombolysis 2011;32:188-94

Contact Information

Office location: Griffith Hall 108L
Mailing address: Box 34
University of Sciences
600 South 43rd Street
Philadelphia, PA 19104-4495
Office Phone: 215-596-8882
Office Fax: 215-596-8586
Email:

j [dot] hollands [at] usciences [dot] edu